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Relationship between antiphospholipid antibodies
and progression of lower extremity arterial occlusive
disease after lower extremity bypass operations
Everett Y. Lam, MD, Lloyd M. Taylor, Jr, MD, Gregory J. Landry, MD, John M. Porter, MD, and
Gregory L. Moneta, MD, Portland, Ore
Purpose: Antiphospholipid antibodies (APLs), which consist of anticardiolipin antibodies (ACLs) or lupus anticoagu-
lant (LA), are associated with venous thrombosis, stroke, and cardiac events. Although they are present in many
patients with lower extremity atherosclerotic occlusive disease (LEAOD), the relationship between APL and the pro-
gression of LEAOD has not been reported. A comparison of progression of LEAOD as determined with direct imag-
ing studies in patients with and without APL forms the basis for this report.
Methods: APL+ patients (immunoglobulin M [IgM] or IgA or IgG ACL > 3 SD units above control mean or positive
LA) who underwent lower extremity bypass grafting between January 1990 and June 1999 (n = 79) were compared
with an APL control group (n = 68). Members of the study and control groups were similar with respect to age, pro-
cedure, sex, length of follow-up, and multiple atherosclerosis risk factors. Progression of LEAOD was determined by
comparing preoperative arteriograms with postoperative imaging studies (arteriograms or duplex scanning). External
iliac, common femoral, superficial femoral and popliteal arteries were graded as < 50% stenosis, ≥ 50% stenosis, or
occluded. Posterior tibial and anterior tibial arteries were graded as patent or occluded. Progression was defined as any
increase in stenosis category. 
Results: The mean follow-up period was 31 months for APL+ and 35 months for APL– patients (P = not significant).
Progression of LEAOD occurred in 58 (73%) of 79 APL+ patients and in 25 (37%) of 68 APL– patients (P < .001).
There was no difference in progression in external iliac or common femoral arteries. Differences in progression were
noted in more distal arteries; APL+ patients had significantly more progression in superficial femoral (45% vs 16%, 
P < .01), popliteal (31% vs 12%, P < .01), posterior tibial (29% vs 13%, P < .05), and anterior tibial arteries (29% vs
14%, P < .05). Multivariate logistic regression analysis showed a significant independent association between the pres-
ence of APL and progression of LEAOD (P < .0001).
Conclusion: In this study, the presence of APL in patients undergoing lower extremity bypass operations was a signifi-
cant independent risk factor for progression of LEAOD. We conclude that this patient group should be closely moni-
tored in the postoperative period and appears ideally suited for prospective studies of therapies to modify LEAOD
progression. (J Vasc Surg 2001;33:976-82.)
An association between antiphospholipid antibodies
(APLs) and vascular thrombotic events was first described
in 1953 in patients with systemic lupus erythematosus.1
APLs include anticardiolipin antibodies (ACLs) and lupus
anticoagulant (LA) and have been demonstrated with a
prevalence of 25.6% in patients undergoing vascular
surgery.2 Relationships have been reported between the
presence of APLs and recurrent fetal loss,3,4 venous
thrombosis,5 late graft failure after coronary artery bypass
graft,6 major cardiovascular events after myocardial infarc-
tion,7 ischemic stroke,8 transient ischemic attack,9 and
peripheral arterial disease.10-14 Multiple reports on the
association of APLs and lower extremity occlusive disease
have focused on technical outcome measurements of
lower extremity bypass grafts.10,15 However, in no report
has the relationship between APLs and the progression of
lower extremity atherosclerotic occlusive disease (LEAOD)
in patients who have undergone lower extremity revascu-
larization been examined.
In a previously reported prospective comparison of
infrainguinal bypass grafting in patients with and without
APLs, we found that APLs did not adversely affect the
outcome of leg bypass grafts.15 There was not a statisti-
cally significant difference in outcome as assessed with 4-
year life-table primary patency rates. Similarly, no
significant difference was noted between APL+ and APL–
patients in assisted primary patency, limb salvage rates, or
patient survival. Although useful, this information did not
assess the degree of atherosclerotic disease progression in
native arteries in this patient population.
In this study, LEAOD progression in APL+ and APL–
patients was directly assessed with either follow-up
angiography or arterial duplex scanning. The accuracy of
duplex scanning of lower extremity arteries in our labora-
tory has been reported and allows for noninvasive direct
evaluation of the lower extremity arterial circulation from
the aortic bifurcation to the ankle.16 This study was
designed to address the following questions: First, is there
a difference in the progression of LEAOD after lower
extremity revascularizations between APL+ and APL–
patients? Second, do certain arteries demonstrate progres-
sion more frequently in APL+ than in APL– patients?
METHODS
Patients were eligible for inclusion in this study if they
had undergone elective suprainguinal (aortofemoral,
femoral-femoral, iliac endarterectomy, or axillofemoral
bypass grafting) or infrainguinal procedures between
January 1, 1990, and June 1, 1999, for atherosclerotic
occlusive disease on the Vascular Surgery Service of
Oregon Health Sciences University. In addition, they
must have had laboratory testing for ACLs and LA, their
preoperative angiogram, and follow-up at the Oregon
Health Sciences University; their preoperative angiogram
must have been available for review.
Specific details about APL testing procedures at our
institution have been described.2 APL testing at our insti-
tution was routinely performed on patients who demon-
strated LEAOD at an early age (< 50 years), early graft
complications, atherosclerotic disease at multiple arterial
sites, or clinical manifestations of a hypercoagulable state
(venous thromboses, history of multiple spontaneous abor-
tions, early myocardial infarctions). With the exception of
consideration of postoperative warfarin therapy for APL+
patients, APL– and APL+ patients were managed the same
with respect to preoperative and postoperative aspirin ther-
apy (all patients), intraoperative heparinization for periods
of arterial occlusion (all patients), autogenous bypass graft
for infrainguinal revascularization, and prosthetic bypass
graft for suprainguinal procedures (all patients).
Patients were considered APL+ if there were positive
results from either an ACL or LA test. Patients were
considered to be positive for ACL only if their test
results were more than 3 SD over the normal control
levels for immunoglobulin G (IgG), IgM, or IgA. Test
results for the presence of LA were reported as positive,
negative, or equivocal. Only positive results more than 3
SD of the control mean were considered significant to
avoid confusion with transient elevations of APL.
Patients with equivocal test results were not included in
this study. Patients were considered APL– if they were
negative for both ACL and LA. Control patients (APL–)
were selected in a similar manner as APL+ patients with
similar requirements. Not all potentially available con-
trol patients were contacted for study inclusion. Those
patients included as controls were recruited during
scheduled clinic visits during the time data were
acquired for this study.
Each patient was characterized with respect to athero-
sclerotic risk factors, including hypertension, diabetes mel-
litus, hyperlipidemia, chronic renal insufficiency (serum
creatinine level > 1.5 mg/dL on two separate determina-
tions), and smoking during follow-up. In addition, we
recorded whether the patient underwent a suprainguinal
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procedure, an infrainguinal procedure, or both, and the
type of operation.
All patients received aspirin before and after surgery
(325 mg/d). Postoperative warfarin therapy was initiated
in APL+ patients unless clinical contraindications
(increased risk of falling, history of hemorrhagic cerebral
infarcts, blood dyscrasias, severe hepatic or renal disease,
childbearing potential) were present. Twenty APL–
patients received postoperative warfarin therapy for clini-
cal indications (atrial fibrillation, prosthetic cardiac valves,
venous thrombosis, multiple arterial thromboses). The
study was approved by the Institutional Review Board of
the Oregon Health Sciences University.
Baseline lower extremity arteriography. The status
of the arteries on each patient’s initial preoperative arterio-
gram was used as the basis for evaluating subsequent pro-
gression of LEAOD. Only patent arterial segments were
selected for follow-up because obviously, progression of
disease is no longer possible in an occluded arterial seg-
ment. Patent external iliac, common femoral, superficial
femoral, and popliteal arteries were classified as < 50% or
≥ 50% stenosed. Anterior tibial and posterior tibial arteries
that were patent continuously from the level of the
popliteal trifurcation to the ankle were included in this
study. The peroneal artery was not studied because previ-
ous work in our vascular laboratory has shown that it is
Table I. Distribution of follow-up studies
Type of follow-up study APL+ (79 pts) APL– (68 pts)
Angiography 51 (64%) 35 (52%)
Duplex scanning 28 (36%) 33 (48%)
P = NS.
Number (percent) of patients with APLs in this study demon-
strating ACL, LA, or both.
less accurately assessed with duplex scanning than the
anterior and posterior tibial arteries.16
Follow-up studies. Follow-up examination was per-
formed with angiography (58% of examinations) or duplex
scanning (42% of examinations). Fifty-one (64%) of APL+
patients and 35 (52%) of APL– patients underwent
angiography (P = not significant [NS], Table I). Duplex
scanning represented the only procedure obtained solely
for the purposes of the study. Arteriography was obtained
if clinically indicated. Both accuracy and technique of
lower extremity arterial duplex scanning in our laboratory
have been previously reported.16
External iliac, common femoral, superficial femoral,
and popliteal arteries were graded on follow-up angiogra-
phy or duplex examination as < 50% stenosis, ≥ 50% to 99%
stenosis, or occluded. Each anterior and posterior tibial
artery that was continuously patent on the initial preoper-
ative arteriogram was graded on follow-up examination
with regard to whether continuous patency was maintained
from the popliteal trifurcation to the ankle. Disease pro-
gression was defined in the external iliac, common femoral,
superficial femoral, and popliteal arteries as an increase in
one category of stenosis. Progression was defined for the
anterior and posterior tibial arteries as a vessel continuously
patent from the popliteal trifurcation to the ankle subse-
quently becoming either segmentally or totally occluded.
Patient progression was defined as any increase in stenosis
category in any arterial segment examined.
Patient selection. The study patient population was
comprised of APL+ patients who had undergone lower
extremity revascularization between January 1, 1990, and
June 1, 1999, at our institution and who also had a follow-
up angiogram of their lower extremity arteries or con-
sented to a follow-up duplex study of their lower
extremity arteries. The control study population included
a similar number of APL– patients who had undergone
lower extremity revascularization between January 1,
1990, and June 1, 1999, at our institution and who also
had a follow-up angiogram of their lower extremity arter-
ies or consented to a follow-up duplex study of their lower
extremity arteries.
Statistical analysis. Atherosclerotic risk factors were
examined with reference to the presence or absence of APL
with χ2 analysis for conditional variables and one-way
analysis of variance for continuous variables. Multivariate
logistic regression analysis was used to test for the inde-
pendent effect of atherosclerotic risk factors on patient pro-
gression. The statistical program JMP from SAS Institute,
Inc (Cary, NC) was used to perform the statistical analyses.
RESULTS
Patients. A total of 147 patients who underwent elec-
tive suprainguinal or infrainguinal bypass graft operations
and were tested for APL entered into the study; 79 (54%)
patients were in the APL+ group and 68 (46%) patients
were in the APL– group. Of the APL+ patients, 56
patients (71%) had ACL only, 12 patients (15%) had LA
only, and 11 patients (14%) had both (Figure).
The demographics and patient characteristics of APL–
patients are shown in comparison with APL+ patients (APL+
in any form, ACL+ only, LA+ only, and ACL+ and LA+) in
Table II. More APL+ patients had postoperative warfarin
therapy than APL– patients (P = .02). All the other parame-
ters were similar between APL+ and APL– patients. APL+
and APL– patients had similar types of operations (Tables III
and IV). The mean follow-up period was 31 months for
APL+ patients (range, 2-94 months) and 35 months (range,
1-204 months) for APL– patients (P = NS).
Initial arteriogram. In the 79 APL+ patients, 474
arteries were patent on the initial arteriogram and could
be used as a basis for comparison with the follow-up arte-
riogram or duplex scan. There were 91 patent external
iliac arteries, 89 patent common femoral arteries, 65
patent superficial femoral arteries, 91 patent popliteal
arteries, 73 continuously patent posterior tibial arteries,
and 65 continuously patent anterior tibial arteries.
In the 68 APL– patients, 407 arteries were patent on
the initial arteriogram. There were 56 patent external iliac
JOURNAL OF VASCULAR SURGERY
978 Lam et al May 2001
Table II. Comparison of patients with and without APLs*
APL+ APL+ APL+ APL+
APL– (ACL+ or LA+; (ACL+, LA–; (ACL–, LA+; (ACL+, LA+; 
Characteristics (n = 68) n = 79) (P value) n = 56) (P value) n = 12) (P value) n = 11) (P value)
Age (y) 63 66 (NS) 68 (NS) 61 (NS) 65 (NS)
Mean follow-up period (mo) 35 31 (NS) 31 (NS) 31 (NS) 33 (NS)
Male:female 55%:45% 45%:55% (NS) 47%:53% (NS) 38%:62% (NS) 27%:73% (NS)
Heart disease 52% 64% (NS) 69% (.04) 69% (NS) 36% (NS)
Diabetes mellitus 44% 35% (NS) 38% (NS) 31% (NS) 18% (NS)
Hypertension 80% 69% (NS) 76% (NS) 46% (.02) 55% (NS)
Hyperlipidemia 46% 39% (NS) 38% (NS) 46% (NS) 27% (NS)
Smoking history 86% 86% (NS) 87% (NS) 93% (NS) 82% (NS)
Renal failure 20% 17% (NS) 16% (NS) 23% (NS) 9% (NS)
Warfarin therapy 30% 49% (.02) 42% (NS) 54% (NS) 82% (.001)
Suprainguinal procedure 54% 48% (NS) 53% (NS) 39% (NS) 36% (NS)
Infrainguinal procedure 65% 73% (NS) 73% (NS) 77% (NS) 73% (NS)
*All P values are in comparison to APL– patients.
arteries, 59 patent common femoral arteries, 74 patent
superficial femoral arteries, 81 patent popliteal arteries, 65
continuously patent posterior tibial arteries, and 72 con-
tinuously patent anterior tibial arteries. 
Progression of arterial occlusive disease. Fifty-eight
(73%) of the 79 APL+ patients and 25 (37%) of the 68
APL– patients demonstrated progression of arterial occlu-
sive disease in at least one artery during the follow-up
period (P < .0001, Table V). Overall, 124 (26%) of the
474 arteries in APL+ patients and 50 (12%) of the 407
arteries in APL– patients patent on the baseline arterio-
gram progressed on follow-up examination (P = .02).
Proximal arteries did not demonstrate a statistical dif-
ference in progression between APL+ and APL– patients.
Thirteen (14%) of 91 external iliac arteries in APL+
patients and three (5%) of 56 external iliac arteries in
APL– patients progressed (P = NS). Fourteen (16%) of 89
common femoral arteries in APL+ patients and five (9%)
of 59 common femoral arteries in APL– patients pro-
gressed (P = NS).
There were statistical differences in atherosclerotic
occlusive disease progression in distal lower extremity
arteries between APL+ and APL– patients. Twenty-nine
(45%) of 65 superficial femoral arteries in APL+ patients
and 12 (16%) of 74 superficial femoral arteries in APL–
patients progressed (P < .01). Twenty-eight (31%) of 91
popliteal arteries in APL+ patients and 10 (12%) of 81
popliteal arteries in APL– patients progressed (P < .01).
Twenty-one (29%) of 73 posterior tibial arteries in APL+
patients and nine (13%) of 65 posterior tibial arteries in
APL– patients progressed (P < .05). Nineteen (29%) of 65
anterior tibial arteries in APL+ patients and 10 (14%) of
72 anterior tibial arteries in APL– patients progressed 
(P < .05, Table VI).
In APL+ patients, there appeared to be a greater
degree of LEAOD progression in patients not receiving
postoperative warfarin therapy. All APL+ patients were
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considered for warfarin therapy; however, only 39 of the
79 APL+ patients were actually treated with warfarin
because of the presence of absolute or relative contraindi-
cations to anticoagulation. The APL+ patients treated with
warfarin did not differ significantly from the APL+ patients
not treated with warfarin in terms of atherosclerotic risk
factors. APL+ patients treated with warfarin were generally
younger than APL+ patients not treated with warfarin (63
vs 70 years, P = .01). Thirty-three (83%) of 40 APL+
patients not receiving warfarin therapy demonstrated pro-
gression, whereas 25 (64%) of 39 APL+ patients receiving
warfarin progressed (P = .06, Table VII). In APL– patients,
there was no statistical difference in progression between
patients receiving or not receiving postoperative warfarin
therapy. Ten (43%) of 23 APL– patients receiving postop-
erative warfarin therapy demonstrated progression,
whereas 14 (32%) of 45 APL– patients not receiving war-
farin therapy progressed (P = NS).
Multivariate logistic regression analysis was used to test
the effect of atherosclerotic risk factors on patient progres-
sion. Risk factors examined were age, heart disease, dia-
betes mellitus, hypertension, hyperlipidemia, chronic renal
insufficiency, smoking, warfarin therapy, type of procedure,
and APL status. Only the presence or absence of APLs con-
tributed significantly (P < .001, odds ratio 5.0) to progres-
sion in those patients who had undergone elective lower
extremity revascularizations for chronic ischemia.
DISCUSSION
APLs were initially identified in patients with systemic
lupus erythematosus and were associated with thrombotic
Table IV. Distribution of infrainguninal procedures
Type of APL+ APL–
procedure (79 pts) (68 pts) P value
Femoral-tibial 20 18 NS
Femoral-popliteal 36 29 NS
Popliteal-plantar 2 7 NS
Endarterectomy 4 1 NS
Table III. Distribution of suprainguinal procedures
Type of APL+ APL–
procedure (79 pts) (68 pts) P value
Aortobifemoral 12 16 NS
Axillofemoral 13 8 NS
Endarterectomy 5 6 NS
Femoral-femoral 6 5 NS
Iliac-femoral 0 2 NS
Table VI. Number (percent) of individual arteries with
detectable progression of arterial occlusive disease in the
follow-up period
Artery examined APL+ APL– P value
External iliac 13/91 (14%) 3/56 (5%) NS
Common femoral 14/89 (16%) 5/59 (9%) NS
Superficial femoral 29/65 (45%) 12/74 (16%) < .01
Popliteal 28/91 (31%) 10/81 (12%) < .01
Posterior tibial 21/73 (29%) 9/65 (13%) < .05
Anterior tibial 19/65 (29%) 10/72 (14%) < .05
Table V. Number (percent) of patients with detectable
progression of arterial occlusive disease in the follow-up
period
Patients with Patients without
APL status progression progression
APL+ (79 pts) 58 (73%) 21 (27%)
APL– (68 pts) 25 (37%) 43 (63%)
P < .0001 between APL+ patients who progressed versus APL– patients
who progressed.
events in these patients.1 Subsequent reports have identi-
fied the presence of APLs in patients without systemic
lupus erythematosus. The exact mechansim by which
APLs affect arterial occlusive disease remains to be clari-
fied. APLs are a heterogenous population of antibodies that
requires a protein cofactor to react with phospholipids. The
cofactor for ACL is β2-glycoprotein I. β2-Glycoprotein I is
a 50-kd glycoprotein present in human plasma and is able to
inhibit the intrinsic blood coagulation pathway, ADP-medi-
ated platelet aggregation, and prothrombinase activity of
activated platelets, acting as a natural anticoagulant. When
ACL binds with β2-glycoprotein I, the anticoagulative
properties of β2-glycoprotein I may be negated, and
endothelial damage and arterial occlusion may ensue.
The cofactor for LA is prothrombin, and the binding of
LA to prothrombin may interfere with the fibrinolytic
cascade.17
We have previously reported a prevalence of 25.6%
APLs in a cross-sectional study of patients with severe
peripheral vascular disease requiring operative interven-
tion.2 The prevalence of APL+ patients in our practice is
surprising, given the requirement that to be considered
APL+, patients must have ACL levels of IgM, IgA, or IgG
greater than 3 SD over the control mean. Elevated ACL
titers more than 2 SD may sometimes be induced by drugs
(pheothiazines, procainamides, chlorothiazide, phenytoin,
quinine, hydralazine) or by certain medical conditions
(solid organ and hematologic malignancies, end-stage renal
failure, syphilis). In addition, the frequency of ACLs has
been noted to increase with age in healthy individuals.18,19
In our previous studies,2,15 we have set ACL titers more
than 3 SD as criteria for APL positivity to minimize the
effects of drugs, medical conditions, and age on ACL levels.
Despite the prevalence of APLs in patients requiring
vascular surgery,2 little is known about the effect of APLs
on the natural history of LEAOD progression of native
arteries in patients who have undergone lower extremity
bypass graft for chronic ischemia. Previous reports have
focused on the effects of APLs on bypass graft patency and
postoperative bypass graft–related complications.* To our
knowledge, this study represents the first attempt to com-
pare LEAOD progression in patients with and without
APLs and to determine the relationship between the pres-
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ence of APLs and the progression of arterial disease in
individual lower extremity arteries.
This study has demonstrated that progression of
LEAOD after revascularization occurs more frequently in
patients with APLs than in patients without APLs. After a
mean follow-up of 31 months, 73% of the 79 APL+
patients evaluated had progression of LEAOD on follow-
up angiographic or duplex scan examination, whereas pro-
gression occurred in only 37% of 68 APL– patients after a
mean follow-up of 35 months (P < .0001).
A previous report from our institution indicated no
difference in late graft failure between APL+ and APL–
patients. The current report, however, focuses on native
vessel progression of occlusive disease, whereas our pre-
vious report focused on vein bypass graft failures. It is
well known that considerable progression of disease can
occur in native vessels without vein graft failure and that
the large majority of vein grafts fail because of lesions
intrinsic to the vein graft. It is therefore not surprising
that a study focusing on progression of native artery dis-
ease in APL+ versus APL– patients could demonstrate a
difference between the two groups while vein graft fail-
ure rates would not be influenced by the presence of
APLs.
Not all arteries appear to be affected equally by the
presence of APLs. We found no difference in progression
in the external iliac and common femoral arteries in APL+
versus APL– patients. However, more distal arteries
(superficial femoral, popliteal, posterior tibial, and anterior
tibial) demonstrated a significantly greater disease pro-
gression in APL+ patients. The larger caliber, more proxi-
mal arteries appear less affected by APLs. Perhaps the
relative hypercoagulable state induced by the presence of
APLs is manifested more prominently in smaller caliber,
lower flow arteries.
It is important to keep in perspective the type of
patients studied for this report. All patients had undergone
previous vascular surgery for LEAOD to qualify for this
study. The Vascular Surgery Service at our hospital is a ter-
tiary referral service, and as such, there was a high inci-
dence of previously failed reconstructions in the patients
we encountered. Clearly, the patients in this study repre-
sented the severe end of the spectrum of patients with
peripheral arterial occlusive disease.
From the data presented, it is reasonable to conclude
that patients with APL who have required previous vascu-
lar surgery for chronic lower extremity ischemia have more
progression of LEAOD than vascular surgical patients
without APLs who underwent previous arterial recon-
struction for LEAOD. However, the effect of APL on the
progression of vascular disease in other less severely
affected patients with LEAOD cannot be inferred from
this study. Perhaps a lower burden of atherosclerotic
occlusive disease in patients with a more mildly affected
peripheral vascular disease would somewhat negate the
effects of APLs. The effect of APLs on the progression of
LEAOD in patients with minimal to moderate peripheral
atherosclerotic occlusive disease remains unknown.
Table VII. Number (percent) of patients with APLs
receiving and not receiving postoperative warfarin 
therapy with detectable progression of arterial occlusive
disease in the follow-up period
Warfarin therapy Progressed Not progressed
Yes 25 (64%) 14 (36%)
No 33 (83%) 7 (17%)
P = .06 betweeen patients who progressed taking warfarin versus patients
who progressed not taking warfarin.
*References 2, 10-12, 14, 15, 20-22.
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The current data suggest that patients with APLs and
severe LEAOD may benefit from warfarin anticoagulation
with regard to progression of arterial disease. Whether the
potential favorable effects of anticoagulation in APL+
patients is due to decreasing the deposition of plaque or
moderating the hypercoagulative effects of the circulating
APL is unknown. There is, however, no reason to suspect
that warfarin acts to diminish actual plaque deposition in
patients with atherosclerosis. However, this should not be
extrapolated as a recommendation for anticoagulation in
any patient with APLs. Similarly, the ability of warfarin to
influence clinical end points of amputation, the develop-
ment of ischemic rest pain, or ulceration in patients with
APLs cannot be inferred from this study. A larger study of
prospectively identified and followed up patients will be
required to determine if the clinical course of APL+
patients with LEAOD and vascular reconstruction can be
altered with antithrombotic therapy.
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Dr Everett Y. Lam. To address your multiple questions, the
first question regarding correlation with previous observations,
this study was purely an anatomic study. We did not look at bypass
outcomes in this study.
Also, in regard to whether bypass is protective for lower
extremity progression, we had published a paper in 1995 by
McLafferty et al that it did not show a difference between opera-
tive and nonoperated limbs in that study.
Patients identified in this study were as follows: patients were
routinely tested for antiphospholipid antibodies who demon-
strated lower extremity occlusive disease at an early age, who had
early graft complications, who had atherosclerotic disease at mul-
tiple sites, and who also manifested other symptoms of hyperco-
agulability such as venous thrombosis, history of multiple
spontaneous abortions, or early myocardial infarctions.
We did not obtain histologic data, but that would be an
interesting study to pursue.
Antiphospholipid antibodies testing at our institution
changed at the end of 1999 with respect to reference values.
DISCUSSION
However, the patients were identified prior to that date and were
tested under the protocols outlined in the presentation.
In addition, patients were only considered positive if they
were greater than 3 SD above the control mean. Patients with
equivocal anticardiolipin titers with less than three standard devi-
ation patients were not included in this study.
The big picture I think is that progression seems to occur
more in antiphospholipid antibody positive patients and that war-
farin may help to alleviate this progression in that population.
Dr Robert Rutherford (Silverthorne, Colo). I’d like you just
to clarify your baseline for change because you did mention pre-
operative imaging studies.
Did you use a postoperative baseline? Was it a postoperative
imaging, and if so, when was that done?
Dr Lam. The preoperative baseline is the angiogram per-
formed prior to operation. The postoperative study is the one
where either they had arteriogram for arterial indications or they
consented to a duplex mapping.
Dr Rutherford. What was your baseline for showing progres-
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sion? Was it the preoperative study, or was it a postoperative study?
Dr Lam. The baseline was the preoperative study.
Dr Richard Treiman (Los Angeles, Calif). I have some clini-
cal questions to ask you. Do you recommend all patients with
findings of vascular disease be tested for these antibodies, and if
you do, do you have a sense of how many patients with either
arterial disease or venous disease will test positive?
Then I’d like to ask you, if you have a patient who does test
positive, do you think these patients should be treated with anti-
coagulants regardless if they’re being operated on or not?
I have one last comment. You have a total of 79 patients
you’ve divided into approximately five categories. The power of
that for statistical significance drops way down when you start
getting your P values in those categories. Do you think that was
statistically significant?
Dr Lam. With regard to testing, this patient population
demonstrates the most severe end point, atherosclerotics. They
required operations. If we tested people across the board with just
claudication, that may not be applicable to this current study. The
prevalence in that patient group may be different.
Again, anticoagulation for the patients who do not have bypass
surgery and are not in the severe category cannot be extrapolated
from the study as this patient population is of the severe group, and
I think our statistics are accurate in what we’ve presented.
Dr Victor Bernhard (Palisades, Calif). I am just curious about
the possible relationship of aspirin or any of the antiplatelet drugs.
Did you stratify for this in your studies to know whether they
might have had an impact?
Dr Lam. Patients in this study all received aspirin. We did not
look at the individual antiplatelet or newer antiplatelet agents in
this study.
Dr Ralph Dilley (LaJolla, Calif). Most of us after lower
extremity bypass make some effort to alter risk factors, particu-
larly control of hypertension, attempts to allow the patient to stop
smoking.
When did you record the risk factor associations in your
study, and during this study was there any attempt to change
these risk factors, like better control of hypertension, cessation
of smoking? Is it possible any of these could have influenced
the results?
Dr Lam. Risk factors were recorded at presentation. However,
smoking was identified during the course of the study. So the
smoking was any history of smoking during the time of this study.
The only active therapy is the warfarin therapy.
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